From: Systemic inflammatory markers of persistent cerebral edema after aneurysmal subarachnoid hemorrhage
Variables | Univariable | Multivariablea | Multivariableb | ||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p value | OR | 95% CI | p value | OR | 95% CI | p value | |
Eotaxin | |||||||||
 Eotaxin (T1), per 1 pg/mL increase | 1.011 | 0.999–1.023 | 0.084 | 1.016 | 1.002–1.030 | 0.029 | 1.011 | 0.996–1.026 | 0.137 |
 Eotaxin (T2), per 1 pg/mL increase | 1.002 | 0.987–1.016 | 0.815 | N/A |  |  |  |  |  |
 Eotaxin (T3), per 1 pg/mL increase | 1.009 | 0.996–1.022 | 0.169 | 1.013 | 0.998–1.023 | 0.080 | 1.012 | 0.995–1.029 | 0.169 |
 Eotaxin (T4), per 1 pg/mL increase | 1.009 | 1.00–1.018 | 0.063 | 1.012 | 1.001–1.023 | 0.030 | 1.019 | 1.002–1.035 | 0.024 |
GCSF | |||||||||
 GCSF (T1), per 1 pg/mL increase | 1.003 | 0.999–1.008 | 0.172 | 1.004 | 0.999–1.009 | 0.157 | 1.003 | 0.997–1.009 | 0.280 |
 GCSF (T2), per 1 pg/mL increase | 0.995 | 0.985–1.006 | 0.386 | N/A |  |  |  |  |  |
 GCSF (T3), per 1 pg/mL increase | 1.004 | 0.988–1.010 | 0.154 | 1.015 | 1.000–1.030 | 0.054 | 1.013 | 0.994–1.031 | 0.175 |
 GCSF (T4), per 1 pg/mL increase | 1.007 | 1.000–1.014 | 0.064 | 1.009 | 0.996–1.022 | 0.186 | 1.007 | 0.922–1.022 | 0.366 |
IL-10 | |||||||||
 IL-10 (T1), per 1 pg/mL increase | 1.003 | 0.999–1.007 | 0.168 | 1.005 | 0.999–1.011 | 0.076 | 1.003 | 0.996–1.011 | 0.350 |
 IL-10 (T2), per 1 pg/mL increase | 0.994 | 0.974–1.014 | 0.525 | N/A |  |  |  |  |  |
 IL-10 (T3), per 1 pg/mL increase | 1.006 | 0.968–1.046 | 0.757 | N/A |  |  |  |  |  |
 IL-10 (T4), per 1 pg/mL increase | 1.004 | 0.993–1.014 | 0.499 | N/A |  |  |  |  |  |
PDGF-AA | |||||||||
 PDGF-AA (T1), per 10 pg/mL increase | 1.001 | 1.000–1.001 | 0.216 | N/A |  |  |  |  |  |
 PDGF-AA (T2), per 10 pg/mL increase | 0.998 | 0.996–1.001 | 0.214 | N/A |  |  |  |  |  |
 PDGF-AA (T3), per 10 pg/mL increase | 1.000 | 0.999–1.001 | 0.849 | N/A |  |  |  |  |  |
 PDGF-AA (T4), per 10 pg/mL increase | 1.000 | 1.000–1.001 | 0.143 | 1.005 | 1.000–1.011 | 0.072 | 1.006 | 0.999–1.014 | 0.075 |
sCD40L | |||||||||
 sCD40L (T1), per 10 pg/mL increase | 0.998 | 0.992–1.003 | 0.419 | N/A |  |  |  |  |  |
 sCD40L (T2), per 10 pg/mL increase | 0.993 | 0.983–1.003 | 0.173 | N/A |  |  |  |  |  |
 sCD40L (T3), per 10 pg/mL increase | 0.998 | 0.995–1.001 | 0.281 | N/A |  |  |  |  |  |
 sCD40L (T4), per 10 pg/mL increase | 1.000 | 1.000–1.000 | 0.060 | 1.003 | 1.001–1.006 | 0.016 | 1.003 | 1.000–1.006 | 0.053 |
IL1Ra | |||||||||
 IL1Ra (T1), per 1 pg/mL increase | 1.001 | 1.000–1.003 | 0.102 | 1.002 | 1.000–1.004 | 0.103 | 1.000 | 0.998–1.003 | 0.814 |
 IL1Ra (T2), per 1 pg/mL increase | 1.001 | 0.997–1.005 | 0.531 | N/A |  |  |  |  |  |
 IL1Ra (T3), per 1 pg/mL increase | 1.002 | 0.999–1.004 | 0.144 | 1.002 | 1.000–1.005 | 0.071 | 1.001 | 0.998–1.004 | 0.497 |
 IL1Ra (T4), per 1 pg/mL increase | 1.000 | 0.996–1.003 | 0.917 | N/A |  |  |  |  |  |
IL-6 | |||||||||
 IL-6 (T1), per 1 pg/mL increase | 1.014 | 1.005–1.023 | 0.003 | 1.015 | 1.004–1.026 | 0.006 | 1.008 | 0.996–1.021 | 0.200 |
 IL-6 (T2), per 1 pg/mL increase | 1.002 | 0.990–1.015 | 0.696 | N/A |  |  |  |  |  |
 IL-6 (T3), per 1 pg/mL increase | 1.014 | 1.002–1.026 | 0.024 | 1.018 | 1.002–1.034 | 0.025 | 1.009 | 0.991–1.027 | 0.331 |
 IL-6 (T4), per 1 pg/mL increase | 1.002 | 0.996–1.008 | 0.535 | N/A |  |  |  |  |  |
IL-8 | |||||||||
 IL-8 (T1), per 1 pg/mL increase | 1.018 | 1.000–1.037 | 0.047 | 1.015 | 0.995–0.948 | 0.135 | 1.013 | 0.990–1.036 | 0.276 |
 IL-8 (T2), per 1 pg/mL increase | 1.018 | 0.992–1.045 | 0.177 | 1.017 | 0.988–1.047 | 0.255 | 1.007 | 0.972–1.043 | 0.695 |
 IL-8 (T3), per 1 pg/mL increase | 1.002 | 0.999–1.005 | 0.221 | N/A |  |  |  |  |  |
 IL-8 (T4), per 1 pg/mL increase | 1.010 | 0.987–1.034 | 0.398 | N/A |  |  |  |  |  |
MCP-1 | |||||||||
 MCP-1 (T1), per 1 pg/mL increase | 1.001 | 0.999–1.003 | 0.220 | N/A |  |  |  |  |  |
 MCP-1 (T2), per 1 pg/mL increase | 1.001 | 0.997–1.005 | 0.723 | N/A |  |  |  |  |  |
 MCP-1 (T3), per 1 pg/mL increase | 1.001 | 1.000–1.003 | 0.142 | 1.001 | 0.999–1.003 | 0.181 | 1.000 | 0.998–1.002 | 0.741 |
 MCP-1 (T4), per 1 pg/mL increase | 1.002 | 1.000–1.004 | 0.034 | 1.002 | 1.000–1.005 | 0.077 | 1.002 | 0.999–1.004 | 0.171 |
MIP1a | |||||||||
 MIP1a (T1), per 1 pg/mL increase | 0.996 | 0.939–1.056 | 0.893 | N/A |  |  |  |  |  |
MIP1a (T2), per 1 pg/mL increase | 1.000 | 0.940–1.063 | 0.992 | N/A |  |  |  |  |  |
 MIP1a (T3), per 1 pg/mL increase | 1.013 | 0.983–1.044 | 0.393 | N/A |  |  |  |  |  |
 MIP1a (T4), per 1 pg/mL increase | 0.967 | 0.874–1.071 | 0.522 | N/A |  |  |  |  |  |
RANTES | |||||||||
 RANTES (T1), per 1 pg/mL increase | 1.000 | 1.000–1.001 | 0.733 | N/A |  |  |  |  |  |
 RANTES (T2), per 1 pg/mL increase | 1.000 | 0.999–1.001 | 0.591 | N/A |  |  |  |  |  |
 RANTES (T3), per 1 pg/mL increase | 1.000 | 1.000–1.001 | 0.240 | N/A |  |  |  |  |  |
 RANTES (T4), per 1 pg/mL increase | 1.000 | 0.999–1.001 | 0.983 | N/A |  |  |  |  |  |
TNF-α | |||||||||
 TNF-α (T1), per 1 pg/mL increase | 1.014 | 0.951–1.082 | 0.672 | N/A |  |  |  |  |  |
 TNF-α (T2), per 1 pg/mL increase | 0.942 | 0.841–1.055 | 0.304 | N/A |  |  |  |  |  |
 TNF-α (T3), per 1 pg/mL increase | 1.010 | 0.952–1.072 | 0.740 | N/A |  |  |  |  |  |
 TNF-α (T4), per 1 pg/mL increase | 1.081 | 1.081–1.155 | 0.022 | 1.117 | 1.027–1.214 | 0.010 | 1.096 | 0.999–1.202 | 0.053 |